Skip to main content
. 2022 Aug 4;74(11):1822–1828. doi: 10.1002/acr.24901

Figure 2.

Figure 2

Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) response in patients receiving intravenous belimumab therapy from a pooled interim analysis of BLISS‐52 and BLISS‐76 long‐term extension studies (BEL112233 and BEL112234), overall at study years 5–6 (A), and stratified by baseline SDI score (B), disease activity at study years 5–6 (C), and proteinuria status at study years 5–6 (D) (34, 36, 37). SELENA–SLEDAI = Safety of Estrogens in Lupus Erythematosus National Assessment–SLE Disease Activity Index. Panel (B) reproduced, with permission, from ref. 36.